Silence Therapeutics PLC (SLN) - Stock & Dividends
Exchange: USA Stocks • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US82686Q1013
Silence Therapeutics plc is a biotechnology company that focuses on developing innovative treatments for various diseases by harnessing the power of short interfering ribonucleic acid (siRNA). This cutting-edge technology allows the company to inhibit the expression of specific genes, providing a potential solution for a range of debilitating conditions.
The company's proprietary mRNAi GalNAc Oligonucleotide Discovery platform is a game-changer in the field of gene therapy. By precision-engineering product candidates, Silence Therapeutics can target specific disease-associated genes in the liver, offering new hope for patients suffering from rare and debilitating diseases.
Silence Therapeutics has a robust pipeline of promising candidates, including Zerlasiran (SLN360), which is currently in phase 2 clinical trials for cardiovascular disease associated with elevated lipoprotein(a). Another notable candidate is Divesiran (SLN124), an siRNA molecule being developed to treat genetic hematological conditions, including polycythemia vera.
In addition to its internal development programs, Silence Therapeutics has established strategic collaborations with leading pharmaceutical companies, including AstraZeneca PLC, Hansoh Pharmaceutical Group Company Limited, and Mallinckrodt Pharma IP Trading DAC. These partnerships aim to accelerate the discovery, development, and commercialization of siRNA therapeutics for a range of diseases, including cardiovascular, renal, metabolic, and respiratory diseases.
With a rich history dating back to 1994, Silence Therapeutics plc has undergone significant transformations, including a name change from SR Pharma plc in 2007. Today, the company is headquartered in London, United Kingdom, and continues to push the boundaries of gene therapy and RNA interference technology.
For more information on Silence Therapeutics plc, please visit their website at https://www.silence-therapeutics.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
SLN Stock Overview
Market Cap in USD | 1,071m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2020-09-08 |
SLN Stock Ratings
Growth 5y | 0.95 |
Fundamental | -51.9 |
Dividend | - |
Rel. Performance vs Sector | 12.78 |
Analysts | 4.40/5 |
Fair Price Momentum | 36.14 USD |
Fair Price DCF | - |
SLN Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
SLN Growth Ratios
Growth 12m | 284.62% |
Growth Correlation 12m | 76% |
Growth Correlation 3m | -41% |
CAGR 5y | 4.56% |
CAGR/Mean DD 5y | 0.12 |
Sharpe Ratio 12m | 3.56 |
Alpha vs SP500 12m | 246.71 |
Beta vs SP500 5y weekly | 1.42 |
ValueRay RSI | 61.99 |
Volatility GJR Garch 1y | 63.97% |
Price / SMA 50 | 3.32% |
Price / SMA 200 | 46.59% |
Current Volume | 121.2k |
Average Volume 20d | 145.6k |
External Links for SLN Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of May 19, 2024, the stock is trading at USD 23.00 with a total of 121,162 shares traded.
Over the past week, the price has changed by +8.44%, over one month by +6.68%, over three months by +3.74% and over the past year by +322.02%.
According to ValueRays Forecast Model, SLN Silence Therapeutics PLC will be worth about 40.7 in May 2025. The stock is currently trading at 23.00. This means that the stock has a potential upside of +77%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 57.1 | 148 |
Analysts Target Price | 39.5 | 71.9 |
ValueRay Target Price | 40.7 | 77.0 |